Fractional CMO for Growth Marketers in Medical Devices & MedTech

What fractional cmo means for Growth Marketers in Medical Devices & MedTech

A fractional CMO sets the marketing strategy, defines positioning and the ICP, builds the channel plan, and leads or coaches the execution team. They give a growing company senior judgment without the cost or commitment of a full-time hire.

For Growth Marketers, the challenge is compounded: Growth marketers live in experiment cycles — hypothesis, test, measure, iterate. The constraint is always execution velocity: not enough hours to run the tests fast enough to find the winners. Growth stalls when the test queue backs up. In Medical Devices & MedTech specifically, Hospital value analysis committee (VAC) reviews are the primary purchase gate for capital equipment and novel devices — a device that has clinical champion support but fails economic justification (no published cost-effectiveness data, no reimbursement code, no comparable reduction in length of stay) does not get approved — plus FDA 21 CFR Part 807 (510(k) clearance process); FDA 21 CFR Part 814 (PMA process for Class III devices); FDA Off-Label Promotion prohibition (device labeling and promotion must match cleared indications); Physician Payments Sunshine Act (Open Payments) reporting for physician KOL relationships; Anti-Kickback Statute implications for device incentives; HIPAA for any patient data used in clinical studies; EU MDR (Medical Device Regulation) and IVDR for European device marketing; ISO 13485 quality system certification as marketing credibility signal; GDPR for clinical study and registry data involving EU patients. That means fractional cmo needs to be executed against Medical Devices & MedTech channels (Clinical specialty society conferences (ACC, ASN, AAOS, AANS, SAGES, DDW — by clinical specialty), Medical device trade publications (MedCity News, MassDevice, Fierce Medtech, Medical Design & Outsourcing), LinkedIn (CMO or Chief Medical Officer at health systems, OR/cath lab directors, surgeon KOLs, Hospital Value Analysis Coordinator), GPO marketing programs (Vizient, Premier, HealthTrust preferred vendor marketing channels), Clinical society exhibit halls and physician education programs (CME-supported symposia around major meetings)) and buyer expectations, without adding to the manual workload.

How Hadrian runs fractional cmo for Growth Marketers in Medical Devices & MedTech

Hadrian's agents execute fractional cmo continuously on your live Medical Devices & MedTech brand data — tuned to Medical Devices & MedTech buyers (VP Marketing or VP Commercial at a medical device manufacturer (Series C through public); Product Manager responsible for a specific device line; VP Sales or National Accounts Director managing GPO relationships and IDN accounts; at health systems, a Value Analysis Coordinator or Director of Supply Chain evaluating device portfolios; Interventional Cardiologist, Orthopedic Surgeon, or specialty physician as clinical evaluator and champion) and channels: Clinical specialty society conferences (ACC, ASN, AAOS, AANS, SAGES, DDW — by clinical specialty), Medical device trade publications (MedCity News, MassDevice, Fierce Medtech, Medical Design & Outsourcing), LinkedIn (CMO or Chief Medical Officer at health systems, OR/cath lab directors, surgeon KOLs, Hospital Value Analysis Coordinator), GPO marketing programs (Vizient, Premier, HealthTrust preferred vendor marketing channels), Clinical society exhibit halls and physician education programs (CME-supported symposia around major meetings) — under your approval gate before anything publishes. For a growth marketer, that means fractional cmo is running in the background, not waiting for you to prompt it.

Run 10x more experiments without 10x the team. Hadrian coordinates fractional cmo with your other marketing functions so strategy, execution, and reporting stay aligned across your full Medical Devices & MedTech operation.

The Medical Devices & MedTech context that matters

Medical device marketing that drives adoption requires simultaneous execution on three tracks: clinical evidence (peer-reviewed publications, society presentation abstracts, clinical registry participation), economic justification (published health economic analyses, cost-per-procedure comparisons, length-of-stay impact), and reimbursement support (CPT code coverage, coverage determination letters, payer medical policies). Skipping any track creates a sales ceiling that no campaign can overcome. Sunshine Act-compliant KOL relationship management — where physician education funding and speaking fees are properly documented and reported — is both a compliance requirement and a marketing asset: disclosed, transparent relationships with recognized clinical experts build more credibility than undisclosed ones.

Medical Devices & MedTech buyers are VP Marketing or VP Commercial at a medical device manufacturer (Series C through public); Product Manager responsible for a specific device line; VP Sales or National Accounts Director managing GPO relationships and IDN accounts; at health systems, a Value Analysis Coordinator or Director of Supply Chain evaluating device portfolios; Interventional Cardiologist, Orthopedic Surgeon, or specialty physician as clinical evaluator and champion — every piece of fractional cmo execution needs to match that. Hadrian applies your Medical Devices & MedTech context automatically, so outputs are industry-native by default.

RELATED